Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/109644
Title: Sulforaphane induces oxidative stress and death by p53-independent mechanism: implication of impaired glutathione recycling
Authors: Oliveira, José Miguel P. Ferreira de
Costa, Maria
Pedrosa, Tiago
Pinto, Pedro
Remédios, Catarina
Oliveira, Helena
Pimentel, Francisco 
Almeida, Luís
Santos, Conceição
Issue Date: 2014
Publisher: Public Library of Science
Project: SFRH/BPD/48853/2008 
SFRH/BPD/74868/2010 
metadata.degois.publication.title: PLoS ONE
metadata.degois.publication.volume: 9
metadata.degois.publication.issue: 3
Abstract: Sulforaphane (SFN) is a naturally-occurring isothiocyanate best known for its role as an indirect antioxidant. Notwithstanding, in different cancer cell lines, SFN may promote the accumulation of reactive oxygen species (ROS) and cause cell death e.g. by apoptosis. Osteosarcoma often becomes chemoresistant, and new molecular targets to prevent drug resistance are needed. Here, we aimed to determine the effect of SFN on ROS levels and to identify key biomarkers leading to ROS unbalance and apoptosis in the p53-null MG-63 osteosarcoma cell line. MG-63 cells were exposed to SFN for up to 48 h. At 10 μM concentration or higher, SFN decreased cell viability, increased the%early apoptotic cells and increased caspase 3 activity. At these higher doses, SFN increased ROS levels, which correlated with apoptotic endpoints and cell viability decline. In exposed cells, gene expression analysis revealed only partial induction of phase-2 detoxification genes. More importantly, SFN inhibited ROS-scavenging enzymes and impaired glutathione recycling, as evidenced by inhibition of glutathione reductase (GR) activity and combined inhibition of glutathione peroxidase (GPx) gene expression and enzyme activity. In conclusion, SFN induced oxidative stress and apoptosis via a p53-independent mechanism. GPx expression and activity were found associated with ROS accumulation in MG-63 cells and are potential biomarkers for the efficacy of ROS-inducing agents e.g. as co-adjuvant drugs in osteosarcoma.
URI: https://hdl.handle.net/10316/109644
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0092980
Rights: openAccess
Appears in Collections:I&D CEISUC - Artigos em Revistas Internacionais

Show full item record

SCOPUSTM   
Citations

44
checked on Oct 28, 2024

WEB OF SCIENCETM
Citations

41
checked on Nov 2, 2024

Page view(s)

90
checked on Nov 5, 2024

Download(s)

40
checked on Nov 5, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons